—A new study from California-based researchers reports that things may be getting worse for certain women at risk for endometrial cancer. Here’s what the research team adds to what’s known ...

Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...

By decoding how focal adhesions regulate lysosomal exocytosis, researchers are opening new doors to understanding cancer cell adhesion and migration and exploring innovative therapies targeting ...

The International Federation of Gynecology and Obstetrics (FIGO) staging systems for vulva, cervix, endometrium, and sarcomas have been revised for the first time in over a decade. The purpose of ...

Many cancers come with the risk of recurrence. That’s when the same type of cancer comes back after you have completed treatment and gone into remission. But some cancers, such as ovarian cancer ...

The widespread use of imaging modalities and the continuous improvement in their sensitivity have lead to an increasing number of incidental findings of focal liver masses, either solitary or ...

Several novel methods have been employed in the treatment of prostate cancer. Focal therapy has emerged as a prime example of these therapies when it comes to treating prostate cancer. The ...

The 5-year relative survival rate for most cancers have improved in the last 40 years. The only exceptions are uterine (endometrial) cancer and cervical cancer—whose survival rates have declined.

EMB-09 is under clinical development by EpimAb Biotherapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase ...